Literature DB >> 15142201

Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.

J W Freston1, B L Pilmer, Y-L Chiu, Q Wang, J C Stolle, J S Griffin, C Q Lee.   

Abstract

AIM: To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.
METHODS: Twenty-nine subjects received lansoprazole orally on days 1-7 and intravenous lansoprazole in NaCl on days 8-14. Blood samples were collected on days 1, 7, 8 and 14. Fasting basal acid output and pentagastrin-stimulated maximal acid output were determined on days -1, 8, 9 and 15. Thirty-six different subjects received one of four regimen sequences: intravenous lansoprazole in NaCl, intravenous in polyethylene glycol, per orally, or intravenous placebo, each for 5 days. Twenty-four hour intragastric pH was recorded on days 1 and 5.
RESULTS: Intravenous and per oral lansoprazole for 7 days produced equivalent basal acid output and maximal acid output suppression. Pharmacokinetics and mean pH values with intravenous lansoprazole in NaCl or polyethylene glycol were equivalent. Both produced mean pH and percentages of time pH above 3, 4, 5 and 6 that were significantly greater than did per orally.
CONCLUSIONS: Intravenous lansoprazole inhibits acid secretion as effectively in NaCl as in polyethylene glycol, and its onset of action is faster than per oral lansoprazole.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142201     DOI: 10.1111/j.1365-2036.2004.01942.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

Review 1.  Intravenous lansoprazole: in erosive oesophagitis.

Authors:  Toni M Dando; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Intravenous ilaprazole is more potent than oral ilaprazole against gastric lesions in rats.

Authors:  Gang Yu; Xin-Qiang Lu; Rui-Bin Su; Ze-Hui Gong; He-Zhi Xie; Hai-Tang Hu; Xue-Mei Hou
Journal:  Dig Dis Sci       Date:  2014-05-07       Impact factor: 3.199

3.  Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects.

Authors:  Hongyun Wang; Liwei Lang; Ning Ou; Ruihua Shi; Haitang Hu; Pei Hu; Ji Jiang
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

Review 4.  Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis.

Authors:  Hamita Sachar; Keta Vaidya; Loren Laine
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

5.  Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.

Authors:  Tom A Yates; Laurie A Tomlinson; Krishnan Bhaskaran; Sinead Langan; Sara Thomas; Liam Smeeth; Ian J Douglas
Journal:  PLoS Med       Date:  2017-11-21       Impact factor: 11.069

6.  Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.

Authors:  Lihua Wu; Jian Liu; Yunliang Zheng; You Zhai; Meihua Lin; Guolan Wu; Duo Lv; Jianzhong Shentu
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

7.  Impact of Gastric H+/K+-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects.

Authors:  Lu-Ning Sun; Yang Cao; Yue-Qi Li; Yun-Qian Fang; Hong-Wen Zhang; Mei-Feng Wang; Li-Jun Xie; Juan Chen; Zhi-Cheng Yang; Ming-Liang Bian; Hao Li; Pei-Pei Zhang; Ji-Fu Wei; Ling Meng; Xue-Hui Zhang; Ping Zhao; Yong-Qing Wang
Journal:  Front Pharmacol       Date:  2017-09-22       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.